|
|
 |
Vaccine
Information Statements
VISs by language
Polish-language VISs
Up-to-date
You
are encouraged to distribute the up-to-date English-language
VIS at the same time
as the translation.
Polish-language VISs
Out-of-date
The translations for some VISs on our website are from
previously published English-language versions that have
since been updated. Unfortunately, IAC is not always able to
obtain translations as updates are issued. Please ensure
that your patients receive information consistent with the
current English-language version of the following VISs.
You
are encouraged to distribute the up-to-date English-language
VIS at
the same time as the translation.
|
|
|
This translation does not contain the
following CDC updates:
- Section 1: The
answer has been rewritten by CDC.
- Section 2: There
are now 2 doses; the first dose is 12-15 months and the second
dose is 4-6 years.
- CDC added information
on MMRV.
- The URL for Vaccine
Adverse Event Reporting System (VAERS) has changed to www.vaers.hhs.gov.
- The URL for the
National Vaccine Injury Compensation Programs has changed to
www.hrsa.gov/vaccincompensation.
These translations do not contain the following
CDC updates:
- These translations do not contain the following CDC updates
- The main change is in Section 4, which now mentions Tdap.
- The NVICP and VAERS web addresses have also been updated
- The mortality rate for tetanus in Section 1 changed from 1 out of
10, to 2 out of 10 cases.
- The date changed to 5/17/07.
This translation does not contain the
following CDC updates:
- CDC changed the
indication to 1 year or older and has recommended routine use
for children.
- Section 2: Added
persons who work with primates or in research labs to indications
(routine vaccination).
- Added bullet for "persons
who live in communities that have prolonged outbreaks of hepatitis
A."
- Divided the section
into "Who" and "When" parts.
- Removed southern
Europe from list of regions with high rates of hepatitis A.
- Section 3: Added
bullet about allergy to vaccine component.
- Changed wording,
particularly the statement on pregnancy, and made list into
bullets.
- Minor changes to
part 4, 5, and 6 to be consistent with other recent VISs.
- Removed the section
on immune globulin.
These translations do not contain the
following CDC updates:
- On July 18, the CDC posted an interim
VIS for hepatitis B. There are minor changes throughout, but the main
purpose of the update is to emphasize the birth dose for all children.
- A final version will be developed.
This translation does not contain the
following CDC updates:
- Female patients
are now advised to postpone pregnancy for 4 weeks after receiving
MMR vaccine (version 12/16/98 read "3 months")
- The website of
the Vaccine Adverse Event Reporting System has
been added.
- A new URL for the
National Vaccine Injury Compensation Program
has been added.
This translation does not contain the
following CDC updates:
- The Guillain-Barre
Syndrome (second bullet just above section 6) was changed slightly: "a
few" was replaced by "some" to reflect the additional
cases that were reported.
- Section 5: Under
severe problems, CDC added information about a possible connection
to Guillain-Barre Syndrome.
- Section 1: CDC
changed the words to say, "Of those who live, another
11%-19% lose their arms or legs..."
- Section 3: There
are new recommendations for MCV4. CDC has added that meningococcal
vaccine is recommended for college freshman living in dormitories
and microbiologists who are routinely exposed to meningococcal
bacteria.
- Section 4: It says
MCV4 is a new vaccine that has not been studied in pregnant
women as much as MPSV4 has.
- Section 5: There
is some more information about MCV4.
Translation
provided by Danusia Filipowski, MD, of Walnut Creek, CA, with review by
Marek Bentkowski, MD, and Chris Kinel, MD, of Chicago, ILThis page was updated on
March 13, 2008 |
|
|
IAC Home